Benedikt Fischer1, Wayne Jones, Karen Urbanoski, Roger Skinner, Jürgen Rehm. 1. Centre for Applied Research in Mental Health and Addiction, Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada; Social and Epidemiological Research, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.
Abstract
INTRODUCTION AND AIMS: Prescription opioid analgesic (POA)-related harms constitute a major public health problem in North America. Ontario features above-average POA use levels in Canada and has seen consistent increases in related mortality and morbidity. Recent studies documented strong correlations between POA dispensing levels and related harm outcomes on population levels. We examined correlations between POA dispensing and key POA-related mortality and morbidity indicators in Ontario, 2005-2011. DESIGN AND METHODS: Correlations between (i) annual dispensing levels of four strong POA formulations (fentanyl, hydromorphone, morphine and oxycodone; from IMS Brogan's Compuscript converted to defined daily doses) and POA-related mortality (based on provincial coroner's data) and (ii) annual total POA dispensing and POA-related treatment caseload (from the Drug and Alcohol Treatment Information System) were examined for the study context. RESULTS: Strong and significant correlations were observed between POA dispensing and mortality for three formulations, namely hydromorphone: 0.98 [95% confidence interval (CI) 0.89-1.00; P<0.001], fentanyl: 0.93 (95% CI 0.58-0.99; P=0.003) and oxycodone: 0.93 (95% CI 0.57-0.99; P=0.003), but not morphine (-0.29; 95% CI-0.86-0.59; P=0.523), as well as for treatment when examining congruent years [0.99 (95% CI 0.92-1.00); P<0.001] and when using a 1-year offset (1.00; 95% CI 0.96-1.00; P<0.001). DISCUSSION AND CONCLUSIONS: POA dispensing levels were found to be strongly correlated with mortality and morbidity (treatment) indicators. Targeted and sensible reductions of POA use level would likely constitute a primary measure to reduce POA-related harms on a population level, especially in a jurisdiction with high POA consumption levels.
INTRODUCTION AND AIMS: Prescription opioid analgesic (POA)-related harms constitute a major public health problem in North America. Ontario features above-average POA use levels in Canada and has seen consistent increases in related mortality and morbidity. Recent studies documented strong correlations between POA dispensing levels and related harm outcomes on population levels. We examined correlations between POA dispensing and key POA-related mortality and morbidity indicators in Ontario, 2005-2011. DESIGN AND METHODS: Correlations between (i) annual dispensing levels of four strong POA formulations (fentanyl, hydromorphone, morphine and oxycodone; from IMS Brogan's Compuscript converted to defined daily doses) and POA-related mortality (based on provincial coroner's data) and (ii) annual total POA dispensing and POA-related treatment caseload (from the Drug and Alcohol Treatment Information System) were examined for the study context. RESULTS: Strong and significant correlations were observed between POA dispensing and mortality for three formulations, namely hydromorphone: 0.98 [95% confidence interval (CI) 0.89-1.00; P<0.001], fentanyl: 0.93 (95% CI 0.58-0.99; P=0.003) and oxycodone: 0.93 (95% CI 0.57-0.99; P=0.003), but not morphine (-0.29; 95% CI-0.86-0.59; P=0.523), as well as for treatment when examining congruent years [0.99 (95% CI 0.92-1.00); P<0.001] and when using a 1-year offset (1.00; 95% CI 0.96-1.00; P<0.001). DISCUSSION AND CONCLUSIONS: POA dispensing levels were found to be strongly correlated with mortality and morbidity (treatment) indicators. Targeted and sensible reductions of POA use level would likely constitute a primary measure to reduce POA-related harms on a population level, especially in a jurisdiction with high POA consumption levels.
Authors: Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson Journal: CMAJ Date: 2018-03-26 Impact factor: 8.262
Authors: David L Murphy; Jacob A Lebin; Stevan G Severtson; Heather A Olsen; Nabarun Dasgupta; Richard C Dart Journal: Drug Saf Date: 2018-08 Impact factor: 5.606
Authors: Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace Journal: Lancet Neurol Date: 2015-01-07 Impact factor: 44.182